Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961543 | 0.89 | FAAH (0.59) | FAAHMEN1KMT2AHDAC6F2 | |
| SCHEMBL4966297 | 0.89 | ALDH1A1 (0.55) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14288743 | 0.87 | FAAH (0.50) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14470499 | 0.85 | FAAH (0.51) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14453387 | 0.85 | FAAH (0.48) | FAAHMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8392988 | 0.85 | ALDH1A1 (0.64) | FAAHKMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8395670 | 0.85 | ALDH1A1 (0.64) | FAAHKMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31060150 | 0.85 | FAAH (0.67) | FAAH | |
| SCHEMBL4188668 | 0.84 | KMT2A (0.53) | FAAHKMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8396460 | 0.83 | ALDH1A1 (0.66) | FAAHALDH1A1SMN1; SMN2LMNAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | claimed |
| EP-2023930-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2009-02-18 | — | — | EP | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030752-A2 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008020866-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020866-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON | 2008-02-21 | — | — | WO | disclosed |
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | FAAH, FAAH2, FADS1 | FAAH 1/4885MEN1 4429/4885KMT2A 1456/4885 |
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, NAAA | FAAH 1/4885MEN1 4725/4885KMT2A 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.